Differential Effects ofVascular Endothelial Growth Factor Receptor-2 Inhibitor ZD 6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells : Implications for Use as a SurrogateMarker of Antiangiogenic Activity

@inproceedings{Beaudry2005DifferentialEO,
  title={Differential Effects ofVascular Endothelial Growth Factor Receptor-2 Inhibitor ZD 6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells : Implications for Use as a SurrogateMarker of Antiangiogenic Activity},
  author={Paul Beaudry and Jeremy Force and George N. Naumov and Andrew Wang and Cheryl Baker and Anderson Ryan and Shay Soker and Bruce Evan Johnson and Judah M Folkman and JohnV. Heymach},
  year={2005}
}
Purpose: Circulating endothelial cells (CEC) comprise at least two distinct populations: bone marrow ^ derivedcirculatingendothelialprogenitors (CEP) andmatureCECs derived fromexisting vasculature.We hypothesized that antiangiogenic agents may have differential effects on CEPs andmature CECs and that these changes may serve as a marker of biological activity. Experimental Design:The effect of angiogenesis inhibitors on CECs was evaluated by flow cytometry after vascular endothelial growth… CONTINUE READING
8 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Hematopoietic stem cells and endothelial cell precursors expressTie - 2 , CD 31 and CD 45

  • DA Ingram, LE Mead, H Tanaka
  • Blood Cells Mol Dis
  • 2004

Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord

  • S Monestiroli, P Mancuso, A Burlini
  • BLOOD
  • 2004

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

  • T Takahashi, MasudaH Kalka C
  • Ann Oncol
  • 2004

Phase II studyof the antiangiogenic agent SU 5416 in patients with advanced soft tissue sarcomas

  • DesaiJ HeymachJV, ManolaJ
  • Clin Cancer Res
  • 2004

A randomized trial of bevacizumab , an anti - vascular endothelial growth factor antibody , for metastatic renal cancer

  • YangJC, L Haworth, RM Sherry
  • N EnglJMed
  • 2003

Similar Papers

Loading similar papers…